Loading
A phase 3 trial of Datopotamab deruxtecan, Rilvegostomig, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features is a phase 3 interventional study registered as NCT06564844 by AstraZeneca, with 25 participants enrolled, started 2024-10-15 and due to reach its primary completion in 2027-06-30. Interventions recorded: Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Rilvegostomig, Pemetrexed, AstraZeneca, Cisplatin.
Shares Datopotamab deruxtecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin.
Shares Rilvegostomig, Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Rilvegostomig, Pemetrexed, AstraZeneca, Cisplatin.
Shares Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Cisplatin.
Shares Datopotamab deruxtecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, AstraZeneca, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin.